שם המפרסם:

Golubchik P, Sever J, Zalsman G, Weizman A. Methylphenidate in the treatment of female adolescents with cooccurrence of attention deficit/hyperactivity disorder and borderline personality disorder: a preliminary open-label trial. Int Clin Psychopharmacol. 2008;:228-31.

Golubchik P, Sever J, Weizman A. Influence of methylphenidate treatment on smoking behavior in ADHD/borderline personality disorder adolescent girls. Clinical Neuropharmacology. 2009. 32:239-42.

Finzi-Dottan R, Triwitz YS, Golubchik P. Predictors of stress-related growth in parents of children with ADHD.Res Dev Disabil. 2011;32:510-9.

Finzi-Dottan R, Bilu R, Golubchik P. Aggression and conduct disorder in former Soviet Union immigrant adolescents: The role of parenting style and ego identity. Children and Youth Services Review. 2011;33:918-926.

Golubchik P, Sever J, Weizman A, Zalsman G. .Methylphenidate treatment in pediatric patients with attention-deficit/hyperactivity disorder and comorbid trichotillomania: a preliminary report. Clin Neuropharmacol. 2011;34:108-10.

Golubchik P, Sever J, Weizman A.Low-dose quetiapine for adolescents with autistic spectrum disorder and aggressive behavior: open-label trial.Clin Neuropharmacol. 2011;34:216-9.

Nahshoni E, Golubchik P, Glazer J, Sever J, Strasberg B, Imbar S, Shoval G,Weizman A, Zalsman G.Late potentials in the signal-averaged electrocardiogram in pre-pubertal children with ADHD, before and after methylphenidate treatment. Eur Child Adolesc Psychiatry. 2012;21:75-8.

Golubchik P, Sever J, Finzi-Dottan R, Kosov I, Weizman A. The Factors Influencing Decision Making on Children's Psychiatric Hospitalization: A Retrospective Chart Review. Community Ment Health J. 2013;49:73-8.

Golubchik P, Sever J, Katz N, Shoval G, Weizman A. Handshaking as a measure of social responsiveness in patients with autistic spectrum disorder. Compr Psychiatry. 2012;53:805-8.

Golubchik P, Sever J, Weizman A. Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharmacol. 2013;36:37-41.

Golubchik P, Arad K, Weizman A. ADHD and comorbid sub-syndromal depression (SSD): What is the impact of methylphenidate on mood? Clin Neuropharmacol. 2013;36:141-5.

Golubchik P, Sever J, Weizman A. Methylphenidate treatment in children with
attention deficit hyperactivity disorder and comorbid social phobia. Int Clin
Psychopharmacol. 2014 (20).

Golubchik P, Sever J, Weizman A. ADHD and co-morbid separation anxiety. The role of methylphenidate monotherapy. Int Clin Psychopharmacol.

Golubchik P, Weizman A, ADHD, Methylphenidate and primary encopresis. Psychosomatics. 2009;50:178

Review Articles

Golubchik P, Birger M, Kotler M, Apter A. Psychopathological Characteristics of Imprisoned Adolescents Around the World and in Israel. The Journal of Medicine and Law. 2004; 30, 95-104.

Golubchik P, Sever J, Weizman A. Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD). Harefuah. 2011;150:788-90, 814


Golubchik P, Weizman A. The Role of Neurosteroids in Development of Pediatric Psychopathology. Ritsner MS and Weizman A. (Editors). Neuroactive Steroids in Brain Function, Behavior and Neuropsychiatric Disorders. Novel Strategies for Research and Treatment. Springer Netherlands. 2008. pp 539-553.